Relay Therapeutics, Inc. logo

Relay Therapeutics, Inc. (RLAY) Q1 2025 Earnings

RLAY·Reported May 5, 2025·After market close

Relay Therapeutics, Inc. reported Q1 2025 revenue of $7.7M (-23.3% YoY), beat analyst consensus of $3.8M by $3.9M. Diluted EPS came in at $-0.46 (+25.8% YoY), beat the $-0.50 consensus by $0.04.

Revenue
$7.7Mbeat by $3.9M
Consensus: $3.8M
Diluted EPS
$-0.46beat by $0.04
Consensus: $-0.50
SEC

SEC Filings

Earnings release8-K not filed yet
Quarterly report10-Q · 0000950170-25-063553

Financial Snapshot

Trailing eight quarters through Q1 2025

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q1 2025 Earnings FAQ

Common questions about Relay Therapeutics, Inc.'s Q1 2025 earnings report.

Relay Therapeutics, Inc. (RLAY) reported Q1 2025 earnings on May 5, 2025 after market close.

Relay Therapeutics, Inc. reported revenue of $7.7M and diluted EPS of $-0.46 for Q1 2025.

Revenue beat the consensus estimate of $3.8M by $3.9M. EPS beat the consensus estimate of $-0.50 by $0.04.

Compared to the same quarter a year prior, revenue declined 23.3% from $10.0M a year earlier and diluted EPS grew 25.8% from $-0.62.

You can read the 10-Q periodic report (0000950170-25-063553) directly on SEC EDGAR. The filing index links above go to sec.gov.